Home › Companies › BRIDGEBIO PHARMA INC. › 2024-2025

BRIDGEBIO PHARMA INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and BRIDGEBIO PHARMA INC.’s Form 8-K, filed 2025-06-23 (Item 5.07 on EDGAR). Page generated 02 October 2026.

20Reported items
321Asset managers
3,320Fund votes
2025-06-20Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BRIDGEBIO PHARMA INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by BRIDGEBIO PHARMA INC.

These tallies are BRIDGEBIO PHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BRIDGEBIO PHARMA INC. — official shareholder meeting results, meeting held 2025-06-20
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Neil Kumar, Ph.D.	154,328,316	--	--	2,495,765	--	Majority: yes
Elect Director: Charles Homcy, M.D.	145,872,389	--	--	10,951,692	--	Majority: yes
Elect Director: Douglas A. Dachille	128,916,085	--	--	27,907,996	--	Majority: yes
Elect Director: Ronald J. Daniels	151,032,065	--	--	5,792,016	--	Majority: yes
Elect Director: Andrew W. Lo, Ph.D.	126,242,281	--	--	30,581,800	--	Majority: yes
Proposal 6: Approval of the Adjournment of the Annual Meeting to the Extent There are Insufficient Votes at the Annual Meeting to Approve Any of the Above Proposals The Company's stockholders approved the adjournment of the Annual meeting to the extent that th	131,826,931	41,878,620	171,423	--	--	Majority: yes

Source: BRIDGEBIO PHARMA INC., Form 8-K, filed with the SEC on 2025-06-23 — read the filing on EDGAR.

How asset managers voted at the BRIDGEBIO PHARMA INC. 2024-2025 meeting

Each item below shows how the 321 asset managers that disclosed a BRIDGEBIO PHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BRIDGEBIO PHARMA INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

COMPENSATION

Meeting held 2025-06-20.

Combines 5 wordings of this item as funds reported it.

69% fund support · no official result

FOR 68%AGAINST 31%

The 155 asset managers below cast 69% of the shares they voted on this item FOR (22,367,059 for, 10,167,286 against).

FOR: 22,367,059 (68.3%)AGAINST: 10,167,286 (31.0%)ABSTAIN: 42,076 (0.1%)SPLIT: 182,715 (0.6%)NOT VOTED: 3,210 (0.0%)NO VOTE: 3,050 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Vote
BlackRock	9,884,710	37,089	For
Aisling Capital Management LP	6,068,125	0	For
Charles Schwab	0	2,619,284	Against
FARALLON CAPITAL MANAGEMENT LLC	0	1,742,600	Against
Ensign Peak Advisors, Inc	1,406,005	0	For
PRIMECAP MANAGEMENT CO/CA/	0	823,500	Against
EMERALD MUTUAL FUND ADVISERS TRUST	725,270	0	For
Cormorant Asset Management, LP	711,304	0	For
Northern Trust	0	700,404	Against
EMERALD ADVISERS, LLC	622,029	0	For
PRIMECAP Odyssey Funds	0	521,700	Against
Duquesne Family Office LLC	519,993	0	For
Deep Track Capital, LP	473,161	0	For
Philosophy Capital Management LLC	426,583	0	For
FINANCIAL INVESTORS TRUST	367,591	0	For
Russell Investments	0	338,909	Against
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	0	308,445	Against
Bridge Builder Trust	41,653	246,494	Against
Vanguard	46	282,079	Against
Jackson National	0	236,962	Against
Neuberger Berman	0	222,311	Against
FRONTIER CAPITAL MANAGEMENT CO LLC	0	195,938	Against
QUANTITATIVE MASTER SERIES LLC	195,669	0	For
WCM INVESTMENT MANAGEMENT, LLC	0	0	Split
Tema ETF Trust	150,608	0	For

Showing the 25 largest of 155 asset managers. See all 155 in the interactive database.

2. To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-20.

Combines 2 wordings of this item as funds reported it.

64% fund support · no official result

FOR 64%AGAINST 36%

The 156 asset managers below cast 64% of the shares they voted on this item FOR (68,466,705 for, 37,808,522 against).

FOR: 68,466,705 (64.3%)AGAINST: 37,808,522 (35.5%)ABSTAIN: 212,306 (0.2%)

Largest asset managers voting on “To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Vote
VIKING GLOBAL INVESTORS LP	22,055,375	0	For
Vanguard	15,050,668	14,013	For
State Street	7,331,547	75,494	For
Fidelity	7,017,025	2,500	For
Janus Henderson	4,675,040	70,961	For
Capital Research Global Investors	0	3,569,143	Against
Invesco	0	3,552,204	Against
GEODE CAPITAL MANAGEMENT, LLC	3,524,227	0	For
AllianceBernstein	0	3,306,840	Against
Laurion Capital Management LP	0	2,674,892	Against
Kohlberg Kravis Roberts & Co. L.P.	2,647,100	0	For
JANUS INVESTMENT FUND	2,500,103	0	For
Capital Group	0	1,924,487	Against
PICTET ASSET MANAGEMENT SA	0	1,900,485	Against
John Hancock	0	1,887,568	Against
T. Rowe Price	0	1,829,861	Against
American Century	0	1,725,842	Against
NEW ECONOMY FUND	0	1,557,279	Against
PFM Health Sciences, LP	0	1,023,713	Against
DRIEHAUS CAPITAL MANAGEMENT LLC	0	894,011	Against
Principal	252,964	640,330	Against
Columbia Threadneedle	0	849,002	Against
PRINCIPAL GLOBAL INVESTORS	0	733,826	Against
LORD, ABBETT & CO. LLC	712,421	0	For
Goldman Sachs	925	688,875	Against

Showing the 25 largest of 156 asset managers. See all 156 in the interactive database.

3. To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 5,000,000 shares.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-20.

Combines 2 wordings of this item as funds reported it.

81% fund support · no official result

FOR 80%AGAINST 19%

The 88 asset managers below cast 81% of the shares they voted on this item FOR (39,659,523 for, 9,577,167 against).

FOR: 39,659,523 (80.2%)AGAINST: 9,577,167 (19.4%)ABSTAIN: 238,617 (0.5%)

Largest asset managers voting on “To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option a” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	14,925,612	0	For
Fidelity	5,046,329	2,500	For
BlackRock	5,048,357	0	For
JANUS INVESTMENT FUND	2,500,103	0	For
State Street	2,308,670	2,844	For
Capital Group	0	1,924,487	Against
Invesco	1,597,746	0	For
NEW ECONOMY FUND	0	1,557,279	Against
Charles Schwab	1,297,106	0	For
Principal	428,689	464,900	Against
AllianceBernstein	861,977	0	For
Columbia Threadneedle	849,002	0	For
American Century	0	839,739	Against
T. Rowe Price	0	739,580	Against
Delaware/Macquarie	0	615,753	Against
Lord Abbett	0	614,032	Against
Equitable	580,048	0	For
MUTUAL FUND SERIES TRUST	532,192	0	For
AB DISCOVERY GROWTH FUND, INC.	527,869	0	For
PRIMECAP Odyssey Funds	521,700	0	For
FINANCIAL INVESTORS TRUST	367,591	0	For
TIAA	355,039	0	For
Goldman Sachs	0	350,130	Against
Bridge Builder Trust	101,759	186,388	Against
DRIEHAUS MUTUAL FUNDS	0	272,010	Against

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

4. To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Andrew W. Lo, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD 20%

FOR: 126,242,281WITHHELD: 30,581,800

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Andrew W. Lo, Ph.D.”): 126,242,281 for, 30,581,800 withheld, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,826,023 outstanding shares: 67% for, 16% withheld (83% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (39,646,637 for, 0 against).

FOR 80%ABSTAIN 20%

FOR: 39,646,637 (80.0%)ABSTAIN: 9,886,692 (20.0%)

Largest asset managers voting on “To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	14,924,440	1,172	For
Fidelity	5,046,329	2,500	For
BlackRock	5,048,357	0	For
JANUS INVESTMENT FUND	2,500,103	0	For
State Street	2,308,579	2,935	For
Capital Group	1,924,487	0	For
Invesco	0	1,597,746	Abstain
NEW ECONOMY FUND	1,557,279	0	For
Charles Schwab	1,297,106	0	For
Principal	295	893,294	Abstain
AllianceBernstein	0	861,977	Abstain
Columbia Threadneedle	849,002	0	For
American Century	0	839,739	Abstain
T. Rowe Price	739,580	0	For
Delaware/Macquarie	0	615,753	Abstain
Lord Abbett	0	614,032	Abstain
Equitable	223,954	356,094	Abstain
MUTUAL FUND SERIES TRUST	532,192	0	For
AB DISCOVERY GROWTH FUND, INC.	0	527,869	Abstain
PRIMECAP Odyssey Funds	521,700	0	For
FINANCIAL INVESTORS TRUST	0	367,591	Abstain
TIAA	355,039	0	For
Goldman Sachs	0	350,130	Abstain
Bridge Builder Trust	41,653	246,494	Abstain
DRIEHAUS MUTUAL FUNDS	0	272,010	Abstain

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

5. To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Charles Homcy, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 145,872,389WITHHELD: 10,951,692

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Charles Homcy, M.D.”): 145,872,389 for, 10,951,692 withheld, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,826,023 outstanding shares: 77% for, 6% withheld (83% of the company cast a for/withheld vote).

The 86 asset managers below cast 99.6% of the shares they voted on this item FOR (44,145,176 for, 140,225 against).

FOR 89%11%

FOR: 44,145,176 (89.1%)AGAINST: 140,225 (0.3%)ABSTAIN: 5,247,928 (10.6%)

Largest asset managers voting on “To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	14,925,612	0	For
Fidelity	5,048,829	0	For
BlackRock	5,048,357	0	For
JANUS INVESTMENT FUND	2,500,103	0	For
State Street	9,549	2,301,965	Abstain
Capital Group	1,924,487	0	For
Invesco	1,597,746	0	For
NEW ECONOMY FUND	1,557,279	0	For
Charles Schwab	1,297,106	0	For
Principal	465,195	428,394	For
AllianceBernstein	0	861,977	Abstain
Columbia Threadneedle	849,002	0	For
American Century	839,739	0	For
T. Rowe Price	739,580	0	For
Delaware/Macquarie	615,753	0	For
Lord Abbett	614,032	0	For
Equitable	223,954	356,094	Abstain
MUTUAL FUND SERIES TRUST	532,192	0	For
AB DISCOVERY GROWTH FUND, INC.	0	527,869	Abstain
PRIMECAP Odyssey Funds	521,700	0	For
FINANCIAL INVESTORS TRUST	0	367,591	Abstain
TIAA	355,039	0	For
Goldman Sachs	350,130	0	For
Bridge Builder Trust	288,147	0	For
DRIEHAUS MUTUAL FUNDS	272,010	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

6. To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Douglas A. Dachille

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD 18%

FOR: 128,916,085WITHHELD: 27,907,996

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Douglas A. Dachille”): 128,916,085 for, 27,907,996 withheld, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,826,023 outstanding shares: 68% for, 15% withheld (83% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (41,582,727 for, 0 against).

FOR 84%ABSTAIN 16%

FOR: 41,582,727 (83.9%)ABSTAIN: 7,950,602 (16.1%)

Largest asset managers voting on “To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	14,924,440	1,172	For
Fidelity	5,046,329	2,500	For
BlackRock	5,048,357	0	For
JANUS INVESTMENT FUND	2,500,103	0	For
State Street	2,308,579	2,935	For
Capital Group	1,924,487	0	For
Invesco	1,597,746	0	For
NEW ECONOMY FUND	1,557,279	0	For
Charles Schwab	1,297,106	0	For
Principal	295	893,294	Abstain
AllianceBernstein	0	861,977	Abstain
Columbia Threadneedle	849,002	0	For
American Century	0	839,739	Abstain
T. Rowe Price	739,580	0	For
Delaware/Macquarie	0	615,753	Abstain
Lord Abbett	0	614,032	Abstain
Equitable	223,954	356,094	Abstain
MUTUAL FUND SERIES TRUST	532,192	0	For
AB DISCOVERY GROWTH FUND, INC.	0	527,869	Abstain
PRIMECAP Odyssey Funds	521,700	0	For
FINANCIAL INVESTORS TRUST	0	367,591	Abstain
TIAA	355,039	0	For
Goldman Sachs	0	350,130	Abstain
Bridge Builder Trust	41,653	246,494	Abstain
DRIEHAUS MUTUAL FUNDS	0	272,010	Abstain

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

7. To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Neil Kumar, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 154,328,316WITHHELD: 2,495,765

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Neil Kumar, Ph.D.”): 154,328,316 for, 2,495,765 withheld, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,826,023 outstanding shares: 81% for, 1% withheld (83% of the company cast a for/withheld vote).

The 86 asset managers below cast 99.7% of the shares they voted on this item FOR (48,545,675 for, 140,225 against).

FOR 98%

FOR: 48,545,675 (98.0%)AGAINST: 140,225 (0.3%)ABSTAIN: 847,429 (1.7%)

Largest asset managers voting on “To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	14,925,612	0	For
Fidelity	5,048,829	0	For
BlackRock	5,048,357	0	For
JANUS INVESTMENT FUND	2,500,103	0	For
State Street	2,311,514	0	For
Capital Group	1,924,487	0	For
Invesco	1,597,746	0	For
NEW ECONOMY FUND	1,557,279	0	For
Charles Schwab	1,297,106	0	For
Principal	640,625	252,964	For
AllianceBernstein	861,977	0	For
Columbia Threadneedle	849,002	0	For
American Century	839,739	0	For
T. Rowe Price	739,580	0	For
Delaware/Macquarie	615,753	0	For
Lord Abbett	614,032	0	For
Equitable	580,048	0	For
MUTUAL FUND SERIES TRUST	532,192	0	For
AB DISCOVERY GROWTH FUND, INC.	527,869	0	For
PRIMECAP Odyssey Funds	521,700	0	For
FINANCIAL INVESTORS TRUST	0	367,591	Abstain
TIAA	355,039	0	For
Goldman Sachs	350,130	0	For
Bridge Builder Trust	288,147	0	For
DRIEHAUS MUTUAL FUNDS	272,010	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

8. To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Ronald J. Daniels

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 151,032,065WITHHELD: 5,792,016

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Ronald J. Daniels”): 151,032,065 for, 5,792,016 withheld, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,826,023 outstanding shares: 80% for, 3% withheld (83% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (46,764,530 for, 0 against).

FOR 94%

FOR: 46,764,530 (94.4%)ABSTAIN: 2,768,799 (5.6%)

Largest asset managers voting on “To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	14,925,612	0	For
Fidelity	5,048,829	0	For
BlackRock	5,048,357	0	For
JANUS INVESTMENT FUND	2,500,103	0	For
State Street	2,311,514	0	For
Capital Group	1,924,487	0	For
Invesco	1,597,746	0	For
NEW ECONOMY FUND	1,557,279	0	For
Charles Schwab	1,297,106	0	For
Principal	465,195	428,394	For
AllianceBernstein	0	861,977	Abstain
Columbia Threadneedle	849,002	0	For
American Century	839,739	0	For
T. Rowe Price	739,580	0	For
Delaware/Macquarie	615,753	0	For
Lord Abbett	614,032	0	For
Equitable	223,954	356,094	Abstain
MUTUAL FUND SERIES TRUST	532,192	0	For
AB DISCOVERY GROWTH FUND, INC.	0	527,869	Abstain
PRIMECAP Odyssey Funds	521,700	0	For
FINANCIAL INVESTORS TRUST	0	367,591	Abstain
TIAA	355,039	0	For
Goldman Sachs	350,130	0	For
Bridge Builder Trust	288,147	0	For
DRIEHAUS MUTUAL FUNDS	272,010	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

9. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of our officers as permitted under current Delaware law.

CORPORATE GOVERNANCE

Meeting held 2025-06-20.

98% fund support · no official result

FOR 98%

The 86 asset managers below cast 98% of the shares they voted on this item FOR (48,615,679 for, 812,714 against).

FOR: 48,615,679 (98.3%)AGAINST: 812,714 (1.6%)ABSTAIN: 26,311 (0.1%)

Largest asset managers voting on “To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to include an offic” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	14,924,441	1,171	For
Fidelity	5,048,829	0	For
BlackRock	5,048,357	0	For
JANUS INVESTMENT FUND	2,500,103	0	For
State Street	2,310,160	1,354	For
Capital Group	1,924,487	0	For
Invesco	1,597,746	0	For
NEW ECONOMY FUND	1,557,279	0	For
Charles Schwab	1,297,106	0	For
Principal	893,294	295	For
AllianceBernstein	861,977	0	For
Columbia Threadneedle	849,002	0	For
American Century	839,739	0	For
T. Rowe Price	739,580	0	For
Delaware/Macquarie	615,753	0	For
Lord Abbett	614,032	0	For
Equitable	580,048	0	For
MUTUAL FUND SERIES TRUST	532,192	0	For
AB DISCOVERY GROWTH FUND, INC.	527,869	0	For
PRIMECAP Odyssey Funds	521,700	0	For
FINANCIAL INVESTORS TRUST	367,591	0	For
TIAA	355,039	0	For
Goldman Sachs	350,130	0	For
Bridge Builder Trust	228,041	60,106	For
DRIEHAUS MUTUAL FUNDS	272,010	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

10. To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.

CORPORATE GOVERNANCEMajority of the votes cast: yes

Meeting held 2025-06-20.

76% Majority: yes · of votes cast

FOR 76%AGAINST 24%

FOR: 131,826,931AGAINST: 41,878,620

BRIDGEBIO PHARMA INC.’s own tally for this item (“Proposal 6: Approval of the Adjournment of the Annual Meeting to the Extent There are Insufficient Votes at the Annual Meeting to Approve Any of the Above Proposals The Company's stockholders approved the adjournment of ”): 131,826,931 for, 41,878,620 against, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,826,023 outstanding shares: 69% for, 22% against (92% of the company cast a for/against vote).

The 86 asset managers below cast 70% of the shares they voted on this item FOR (34,456,866 for, 14,898,027 against).

FOR 70%AGAINST 30%

FOR: 34,456,866 (69.7%)AGAINST: 14,898,027 (30.1%)ABSTAIN: 99,811 (0.2%)

Largest asset managers voting on “To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meet” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	14,924,440	1,172	For
Fidelity	5,046,329	2,500	For
BlackRock	5,048,357	0	For
JANUS INVESTMENT FUND	2,500,103	0	For
State Street	6,614	2,304,900	Against
Capital Group	0	1,924,487	Against
Invesco	1,597,746	0	For
NEW ECONOMY FUND	0	1,557,279	Against
Charles Schwab	0	1,297,106	Against
Principal	428,394	465,195	Against
AllianceBernstein	861,977	0	For
Columbia Threadneedle	0	849,002	Against
American Century	0	839,739	Against
T. Rowe Price	0	739,580	Against
Delaware/Macquarie	0	615,753	Against
Lord Abbett	0	614,032	Against
Equitable	580,048	0	For
MUTUAL FUND SERIES TRUST	532,192	0	For
AB DISCOVERY GROWTH FUND, INC.	527,869	0	For
PRIMECAP Odyssey Funds	521,700	0	For
FINANCIAL INVESTORS TRUST	367,591	0	For
TIAA	355,039	0	For
Goldman Sachs	0	350,130	Against
Bridge Builder Trust	41,653	246,494	Against
DRIEHAUS MUTUAL FUNDS	0	272,010	Against

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

11. To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

AUDIT-RELATED

Meeting held 2025-06-20.

99.9% fund support · no official result

FOR 99.9%

The 86 asset managers below cast 99.9% of the shares they voted on this item FOR (49,428,393 for, 0 against).

FOR: 49,428,393 (99.9%)AGAINST: 0 (0.0%)ABSTAIN: 26,311 (0.1%)

Largest asset managers voting on “To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the C” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Vote
Vanguard	14,925,612	For
Fidelity	5,048,829	For
BlackRock	5,048,357	For
JANUS INVESTMENT FUND	2,500,103	For
State Street	2,311,514	For
Capital Group	1,924,487	For
Invesco	1,597,746	For
NEW ECONOMY FUND	1,557,279	For
Charles Schwab	1,297,106	For
Principal	893,589	For
AllianceBernstein	861,977	For
Columbia Threadneedle	849,002	For
American Century	839,739	For
T. Rowe Price	739,580	For
Delaware/Macquarie	615,753	For
Lord Abbett	614,032	For
Equitable	580,048	For
MUTUAL FUND SERIES TRUST	532,192	For
AB DISCOVERY GROWTH FUND, INC.	527,869	For
PRIMECAP Odyssey Funds	521,700	For
FINANCIAL INVESTORS TRUST	367,591	For
TIAA	355,039	For
Goldman Sachs	350,130	For
Bridge Builder Trust	288,147	For
DRIEHAUS MUTUAL FUNDS	272,010	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

12. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-20.

61% fund support · no official result

FOR 48.3%AGAINST 30%ABSTAIN 21%

The 7 asset managers below cast 61% of the shares they voted on this item FOR (316,555 for, 198,929 against).

FOR: 316,555 (48.3%)AGAINST: 198,929 (30.3%)ABSTAIN: 140,225 (21.4%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	316,555	0	0	For
JPMorgan	0	145,040	0	Against
Erste Asset Management GmbH	0	0	140,225	Abstain
Metzler Asset Management GmbH	0	36,603	0	Against
GuideStone	0	16,221	0	Against
Desjardins Global Asset Management Inc.	0	944	0	Against
Granahan Investment Management, LLC	0	121	0	Against

13. Adjourn Meeting

EXTRAORDINARY TRANSACTIONS

Meeting held 2025-06-20.

0% fund support · no official result

10%ABSTAIN 90%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 16,221 against).

AGAINST: 16,221 (10.4%)ABSTAIN: 140,225 (89.6%)

Largest asset managers voting on “Adjourn Meeting” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Erste Asset Management GmbH	0	0	140,225	0	Abstain
GuideStone	0	16,221	0	0	Against

14. Amend Certificate of Incorporation to Provide for the Exculpation of Officers

CORPORATE GOVERNANCE

Meeting held 2025-06-20.

100% fund support · no official result

10%ABSTAIN 90%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (16,221 for, 0 against).

FOR: 16,221 (10.4%)ABSTAIN: 140,225 (89.6%)

Largest asset managers voting on “Amend Certificate of Incorporation to Provide for the Exculpation of Officers” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Erste Asset Management GmbH	0	0	140,225	0	Abstain
GuideStone	16,221	0	0	0	For

15. Amend Omnibus Stock Plan

COMPENSATION

Meeting held 2025-06-20.

0% fund support · no official result

10%ABSTAIN 90%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 16,221 against).

AGAINST: 16,221 (10.4%)ABSTAIN: 140,225 (89.6%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Erste Asset Management GmbH	0	0	140,225	0	Abstain
GuideStone	0	16,221	0	0	Against

16. DIRECTOR

DIRECTOR ELECTIONS

Meeting held 2025-06-20.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (77,821 for, 0 against).

FOR: 77,821 (100.0%)

Largest asset managers voting on “DIRECTOR” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Gabelli	73,500	0	0	0	For
BOSUN ASSET MANAGEMENT, LLC	4,321	0	0	0	For

17. Ratify Deloitte & Touche LLP as Auditors

AUDIT-RELATED

Meeting held 2025-06-20.

10% fund support · no official result

10%AGAINST 90%

The 2 asset managers below cast 10% of the shares they voted on this item FOR (16,221 for, 140,225 against).

FOR: 16,221 (10.4%)AGAINST: 140,225 (89.6%)

Largest asset managers voting on “Ratify Deloitte & Touche LLP as Auditors” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Erste Asset Management GmbH	0	140,225	0	0	Against
GuideStone	16,221	0	0	0	For

18. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-20.

26% fund support · no official result

FOR 26%AGAINST 74%

The 2 asset managers below cast 26% of the shares they voted on this item FOR (114 for, 330 against).

FOR: 114 (25.7%)AGAINST: 330 (74.3%)

Largest asset managers voting on “14A Executive Compensation” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Focus Partners Wealth	40	330	0	0	Against
Simplify Exchange Traded Funds	74	0	0	0	For

19. To approve, on an advisory basis, the compensation of our named executive officers (NEOs), as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-20.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (3,800,457 for, 0 against).

FOR: 3,800,457 (100.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers (NEOs), as disclosed in the” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Frazier Life Sciences Management, L.P.	3,800,457	0	0	0	For
IPConcept (Luxemburg) S.A.	0	0	0	0	--

20. To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-06-21 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 116 against).

AGAINST: 116 (100.0%)

Largest asset managers voting on “To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.” at BRIDGEBIO PHARMA INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
COLDSTREAM CAPITAL MANAGEMENT INC	0	116	0	0	Against
Echo45 Advisors LLC	0	0	0	0	--

Largest BRIDGEBIO PHARMA INC. shareholders voting in 2024-2025

Ranked by the number of BRIDGEBIO PHARMA INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 189,826,023 shares outstanding at the time of that meeting.

Top BRIDGEBIO PHARMA INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	BlackRock	5.23%
2	Aisling Capital Management LP	3.20%
3	Charles Schwab	1.38%
4	FARALLON CAPITAL MANAGEMENT LLC	0.92%
5	Ensign Peak Advisors, Inc	0.74%
6	PRIMECAP MANAGEMENT CO/CA/	0.43%
7	EMERALD MUTUAL FUND ADVISERS TRUST	0.38%
8	Cormorant Asset Management, LP	0.37%
9	Northern Trust	0.37%
10	EMERALD ADVISERS, LLC	0.33%

Reported BRIDGEBIO PHARMA INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BRIDGEBIO PHARMA INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Viking Global Entities	11.62%	DEF14A
Ali J. Satvat	10.40%	DEF14A
Vanguard Group	7.85%	13F
BlackRock	7.04%	13F
KKR Genetic Disorder L.P.	6.99%	13D
JANUS HENDERSON GROUP PLC	6.94%	13G
VIKING GLOBAL INVESTORS LP	6.24%	13D
Farallon Partners, L.L.C.	5.28%	13G
NEIL KUMAR	4.89%	13G
State Street	3.03%	13F

Percentages above are of 189,826,023 shares outstanding, as reported by BRIDGEBIO PHARMA INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BRIDGEBIO PHARMA INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At BRIDGEBIO PHARMA INC.'s shareholder meeting held 2025-06-20, in the 2024-2025 proxy season, 321 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,320 separate fund positions. Their filings are grouped here into 20 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. BRIDGEBIO PHARMA INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on an advisory basis, the compensation of the Company's named executive officers… — the reporting funds cast 69% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

BRIDGEBIO PHARMA INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.